NCT06734585 2025-09-12
Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant
Astellas Pharma Inc
Completed
Clinical Trials
6 trialsNCT04691648 2025-05-31
A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation
Astellas Pharma Inc
Completed
NCT04988555 2025-04-02
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
Sumitomo Pharma America, Inc.
Phase 1/2 Recruiting
NCT05330377 2023-04-25
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
University of Kentucky
Phase 1 Withdrawn
NCT05279859 2022-06-15
HERKULES-4
Erasca, Inc.
Phase 1/2 Withdrawn
NCT03625505 2021-09-14
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
AbbVie
Phase 1 Completed